Cyclica, Arctoris partnership focuses on Alzheimer’s disease
Click Here to Manage Email Alerts
Cyclica and Arctoris have expanded their partnership to progress drug discovery programs for novel neurodegenerative targets, focusing on Alzheimer’s disease, according to a press release.
“Cyclica’s platform and capabilities in combination with the biological assay development of Arctoris will enable us to yield meaningful results and advance research development for patients suffering from Alzheimer’s and other neurodegenerative diseases,” Cyclica CEO and President Naheed Kurji, said in the release.
The companies have long-term plans as discussions are already underway about tackling additional therapeutic targets.
“Our joint drug discovery program focuses on dual specificity inhibitors, a very promising yet also challenging modality,” Martin-Immanuel Bittner, MD, PhD, FRSA, Arctoris CEO, said in the release.